Valore202020212022202320242025TTMSpese di vendita, generali e amministrative2.5 B2.67 B2.4 B2.55 B2.4 B2.43 B2.43 BRicerca e sviluppo3.99 B2.5 B2.23 B2.46 B2.04 B1.86 B1.78 BReddito operativo4.55 B2.84 B9.72 B7.03 B7.18 B2.49 B2.53 BProventi non operativi, Totale497.4 M-1.1 B108.2 M-315.5 M-343.6 M-305.6 M94.7 MOneri finanziari, al netto degli interessi capitalizzati222.5 M253.6 M246.6 M246.9 M250.3 M267.5 M267.5 MProventi non operativi, esclusi gli oneri finanziari272 M-1.34 B-148.5 M-565.9 M-623.5 M-548.4 M-148.1 MEntrate/uscite straordinarie2.9 M-5.6 M10.1 M3.5 M29.6 M-24.7 M-24.7 MUtile al lordo delle imposte5.05 B1.78 B3.59 B1.3 B1.91 B1.56 B1.56 BQuota di utile3.3 M34.9 M2.6 M00——Imposte992.3 M52.5 M632.8 M135.3 M273.8 M263.6 M263.6 MInteressi di minoranza59.9 M171.5 M-85.3 M400 K00—Altri proventi/oneri al netto delle imposte-131.2 M-202.2 M-208.2 M-148.2 M-159.6 M-68.3 M-68.3 MUtile netto al lordo delle attività cessate4 B1.56 B3.05 B1.16 B1.63 B1.29 B1.29 BAttività cessate———————Utile netto4 B1.56 B3.05 B1.16 B1.63 B1.29 B1.29 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari4 B1.56 B3.05 B1.16 B1.63 B1.29 B1.29 BUtile base per azione (EPS base)24.8610.4420.968.0211.218.838.83Utile diluito per azione (EPS diluito)24.810.420.877.9711.188.798.79Numero medio di azioni ordinarie in circolazione160.9 M149.1 M145.3 M144.7 M145.6 M146.5 M585.7 MAzioni diluite in circolazione161.3 M149.6 M146 M145.6 M145.9 M147.1 M587.5 MEBITDA5.01 B3.33 B4.11 B1.79 B2.58 B2.34 B2.34 BEBIT4.55 B2.84 B3.59 B1.3 B1.91 B1.56 B1.56 BCosto del fatturato1.81 B2.11 B2.28 B2.53 B2.31 B2.4 B2.4 BAltri costi del venduto26.6 M167.6 M336.2 M124.4 M101.9 M29.2 M29.2 MAmmortamento e svalutazione (liquidità)457.2 M487.7 M518.4 M494.8 M673.2 M779.9 M779.9 M
Biogen Inc
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.